Vivos Inc (RDGL)

[SC8]

Please just read the financials. IsoPet is generally sold below cost. Even in rare cases where it's sold above cost, there no hope of getting volumes required to become profitable before the cash well runs dry. RDGL has millions in overhead to cover. IsoPet would need very both high margins and high volumes to be profitable. There is no reasonable hope for IsoPet saving RDGL.

It insane that this remains MK's highest priority when the only thing that can save RDGL is getting Radiogel to human trials. Yet here we are in March 2024, and MK has failed to submit a single item that FDA needs to consider Radiogel for human trials.